Randomized clinical trials found that pairing continuous glucose monitoring with an insulin pump that automatically adjusts insulin delivery to glucose levels led to less hypoglycemia and improved A1c—especially when baseline A1c was >8.0%.

Why It Matters To Your Practice

• Type 1 diabetes (a form of Diabetes mellitus [DM]) affects ~2 million people in the U.S. and requires lifelong insulin replacement.

• Closed-loop systems (CGM + pump automation) can reduce day-to-day glycemic variability and treatment burden compared with manual dosing.

• Because up to 44% of children and 23% of adults present in DKA at diagnosis, optimizing ongoing glycemic management is central to preventing acute and long-term complications.

Clinical Benefits

• Less hypoglycemia in randomized trials when CGM is integrated with automated insulin delivery.

• Improved hemoglobin A1c, with the greatest improvements in patients starting above 8.0%.

• More physiologic insulin delivery by continuously titrating basal insulin in response to real-time glucose trends.

Managing Risks

• Auto-adjusting pumps still require patient education on meal boluses, infusion set troubleshooting, and what to do during illness or persistent hyperglycemia.

• Watch for DKA risk if insulin delivery is interrupted (e.g., infusion failure) despite “normal-looking” recent control.

• Confirm patients understand device alarms, CGM lag, and when to verify with fingerstick glucose (e.g., symptoms discordant with CGM readings).

The Bottom Line

• For type 1 DM, closed-loop CGM-pump systems have randomized-trial evidence for less hypoglycemia and better A1c—particularly when baseline A1c is >8.0%.

• Clinical payoff is highest when you pair device prescribing with structured education, sick-day planning, and rapid support for infusion/CGM failures.